Your session is about to expire
What is Copiktra
DuvelisibThe Generic name of this drug
Treatment SummaryDuvelisib, also known as IPI-145 and INK-1197, is a medication designed to reduce the activity of two forms of an enzyme called phosphoinositide-3 kinases. This drug was developed by Verastem, Inc and was approved by the FDA in 2018. It is commonly used to inhibit the activity of both adaptive and innate immune cells.
Copiktrais the brand name
Copiktra Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Copiktra
Duvelisib
2018
6
Effectiveness
How Copiktra Affects PatientsDuvelisib is a medication used to treat certain types of leukemia and lymphoma. In laboratory studies, it was found to be effective at reducing the growth of cancer cells even when other treatments had failed. In clinical trials, it was found to be twice as effective as the drug ofatumumab in treating chronic lymphocytic leukemia or small lymphocytic leukemia, with a median progression-free survival of 16.4 months and an overall response rate of 78%. For patients with follicular lymphoma, the overall response rate was 42%, with 43% of them maintaining the response for at least 6 months and 17% for at
How Copiktra works in the bodyDuvelisib works by blocking the activity of two forms of the protein phosphoinositide3-kinase (PI3K). PI3K plays an important role in the body's immune system and blocking it suppresses the immune response. Duvelisib also blocks the signaling from BCR (B cell receptor), which is critical for the growth and survival of lymphoma cells. It also blocks paracrine and autocrine pro-survival signals, like adhesion molecules, chemokines and soluble factors. By blocking these proteins, duvelisib encourages the recognition and elimination of tumor cells.
When to interrupt dosage
The proposed measure of Copiktra is contingent upon the recognized condition, including Lymphoma, Follicular, Refractory anemias and refractory, relapsed small lymphocytic lymphoma. The amount of dosage is subject to the technique of delivery (e.g. Capsule - Oral or Capsule) specified in the following table.Condition
Dosage
Administration
Therapeutic procedure
15.0 mg, 25.0 mg,
, Capsule, Oral, Capsule - Oral
Refractory Small Lymphocytic Lymphoma
15.0 mg, 25.0 mg,
, Capsule, Oral, Capsule - Oral
Chronic Lymphocytic Leukemia
15.0 mg, 25.0 mg,
, Capsule, Oral, Capsule - Oral
Relapsed Chronic Lymphocytic Leukemia
15.0 mg, 25.0 mg,
, Capsule, Oral, Capsule - Oral
Warnings
There are 20 known major drug interactions with Copiktra.Common Copiktra Drug Interactions
Drug Name
Risk Level
Description
9-aminocamptothecin
Moderate
The metabolism of 9-aminocamptothecin can be decreased when combined with Duvelisib.
Abemaciclib
Moderate
The metabolism of Abemaciclib can be decreased when combined with Duvelisib.
Acalabrutinib
Moderate
The metabolism of Acalabrutinib can be decreased when combined with Duvelisib.
Acenocoumarol
Moderate
The metabolism of Acenocoumarol can be decreased when combined with Duvelisib.
Alectinib
Moderate
The metabolism of Alectinib can be decreased when combined with Duvelisib.
Copiktra Toxicity & Overdose RiskThere is no evidence to suggest that duvelisib is carcinogenic. In fertility studies, some histological abnormalities were observed in rats, including thinning of the seminiferous epithelium in the testes, decreased testes weight, soft testes, small epididymis, low sperm count/absence of sperm, reduced ovary weight, and thinning of the uterus.
Copiktra Novel Uses: Which Conditions Have a Clinical Trial Featuring Copiktra?
167 active trials are in progress to investigate the potential of Copiktra for Therapeutic Procedures, prior therapies, as well as for the treatment of Follicular Lymphoma.Condition
Clinical Trials
Trial Phases
Therapeutic procedure
0 Actively Recruiting
Refractory Small Lymphocytic Lymphoma
16 Actively Recruiting
Phase 1, Phase 2
Relapsed Chronic Lymphocytic Leukemia
7 Actively Recruiting
Phase 2, Phase 1
Chronic Lymphocytic Leukemia
0 Actively Recruiting
Copiktra Reviews: What are patients saying about Copiktra?
1Patient Review
9/13/2019 My husband died after just two weeks of taking this medication. He and I were the only ones who saw the immediate adverse effects; our children didn't even notice anything until it was too late.
1Patient Review
6/9/2019 My husband passed away after using this drug for two weeks.
Patient Q&A Section about copiktra
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How is Duvelisib administered?
"The recommended dose of duvelisib is 25 mg taken orally twice daily in 28-day treatment cycles."
Answered by AI
Who manufactures Copiktra?
"We are going to evaluate the long-term safety of Copiktra by requiring the drug manufacturer, Secura Bio, to submit the final 5-year survival results from the clinical trial called DUO trial. This trial is a phase 3, randomized, open-label trial."
Answered by AI
What is Copiktra used for?
"This medication is used to treat certain types of cancer, such as chronic lymphocytic leukemia and small lymphocytic lymphoma. Duvelisib belongs to a class of drugs known as kinase inhibitors, which work by slowing or stopping the growth of cancer cells."
Answered by AI